A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.

de Graan, Anne-Joy M;Elens, Laure;Smid, Marcel;Martens, John W;Mathijssen, Ron H J;et.al.
(2013) Clinical Cancer Research —

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 321.62 KB
Request a copy

Details

Authors
  • de Graan, Anne-Joy M
    Author
  • Elens, LaureUCLouvain
    Author
  • Smid, Marcel
    Author
  • Martens, John W
    Author
  • Mathijssen, Ron H J
    Author
Show more
Abstract
Paclitaxel is used in the treatment of solid tumors and displays high interindividual variation in exposure. Low paclitaxel clearance could lead to increased toxicity during treatment. We present a genetic prediction model identifying patients with low paclitaxel clearance, based on the drug-metabolizing enzyme and transporter (DMET)-platform, capable of detecting 1,936 genetic variants in 225 metabolizing enzyme and drug transporter genes.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

de Graan, A.-J. M., Elens, L., Smid, M., Martens, J. W., Sparreboom, A., Nieuweboer, A. J. M., Friberg, L. E., Elbouazzaoui, S., Wiemer, E. A. C., van der Holt, B., Verweij, J., van Schaik, R. H. N., & Mathijssen, R. H. J. (2013). A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-13-0487